ReviewPharmaceutics2020
Fibroblast Growth Factor 2-A Review of Stabilisation Approaches for Clinical Applications.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Fibroblast growth factors in ischemic stroke: Therapeutic potential and clinical challenges.Acta pharmacologica Sinica · 2026Review
- Phased affinity-controlled delivery of vascular endothelial growth factor, fibroblast growth factor-2, and platelet derived growth factor enhances in vitro angiogenesis.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Towards Cost-Effective and Sustainable Media Formulations for Terrestrial and Aquatic Cellular Agriculture.Foods (Basel, Switzerland) · 2026Review
- Modern Drug Delivery Platforms Based on Photocrosslinkable Hydrogels (PCHs) in Dentistry: From Material Characteristics to Clinical Applications-A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Understanding the Aggregation Mechanism of and Developing Stabilization Strategies for Recombinant Fibroblast Growth Factor 2.Biomolecules · 2026Article
- FGF-2-Overexpressing Adipose-Derived Stem Cells as a Paracrine Platform for Angiogenesis-Driven Tissue Regeneration.Cellular and molecular bioengineering · 2026Article
- Endogenous FGFs drive ERK-dependent cell fate patterning in 2D human gastruloids.Development (Cambridge, England) · 2026Article
- bFGF Oligomeric Stability Drives Functional Performance in Human Pluripotent Stem Cells.International journal of molecular sciences · 2026Article
- A practical CD90.2-based FACS strategy for obtaining Schwann cell-enriched cultures from adult mouse nerves.Frontiers in cellular neuroscience · 2026Article
- Hyaluronan-Based Hybrid Systems as Growth Factor Carriers in the Treatment of Chronic Wounds.International journal of molecular sciences · 2025Review
- Plasma cytokine profiles in oral and oropharyngeal squamous cell carcinoma.BMC oral health · 2025Article
- From fibro/adipogenic progenitors to adipocytes: Understanding adipogenesis in muscle degeneration for disease modulation.The Journal of physiology · 2025Review
- Modifying Large Molecule Release from Hydrogels Using Microcapillary Channels Patterned with Microfibrous Templates.Polymers for advanced technologies · 2025Article
- Endogenous FGFs drive ERK-dependent cell fate patterning in 2D human gastruloids.bioRxiv : the preprint server for biology · 2025Article
- Long-Gap Sciatic Nerve Regeneration Using 3D-Printed Nerve Conduits with Controlled FGF-2 Release.ACS applied materials & interfaces · 2025Article
- Role of FGF2 in promoting osteogenic differentiation for craniofacial bone regeneration.Regenerative engineering and translational medicine · 2025Article
- Low-cost food-grade alternatives for serum albumins in FBS-free cell culture media.Scientific reports · 2025Article
- FGF2 Mediated USP42-PPARγ Axis Activation Ameliorates Liver Oxidative Damage and Promotes Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Anisotropic structure of nanofiber hydrogel accelerates diabetic wound healing via triadic synergy of immune-angiogenic-neurogenic microenvironments.Bioactive materials · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basic fibroblast growth factor (FGF)-2 has been shown to regulate many cellular functions including cell proliferation, migration, and differentiation, as well as angiogenesis in a variety of tissues, including skin, blood vessel, muscle, adipose, tendon/ligament, cartilage, bone, tooth, and nerve. These multiple functions make FGF-2 an attractive component for wound healing and tissue engineering constructs; however, the stability of FGF-2 is widely accepted to be a major concern for the development of useful medicinal products. Many approaches have been reported in the literature for preserving the biological activity of FGF-2 in aqueous solutions. Most of these efforts were directed at sustaining FGF-2 activity for cell culture research, with a smaller number of studies seeking to develop sustained release formulations of FGF-2 for tissue engineering applications. The stabilisation approaches may be classified into the broad classes of ionic interaction modification with excipients, chemical modification, and physical adsorption and encapsulation with carrier materials. This review discusses the underlying causes of FGF-2 instability and provides an overview of the approaches reported in the literature for stabilising FGF-2 that may be relevant for clinical applications. Although efforts have been made to stabilise FGF-2 for both in vitro and in vivo applications with varying degrees of success, the lack of comprehensive published stability data for the final FGF-2 products represents a substantial gap in the current knowledge, which has to be addressed before viable products for wider tissue engineering applications can be developed to meet regulatory authorisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.